Table 7

Impact of remission and LDA on HRQoL*

AuthorsCountry/regionYear of publicationPatientsFollow-up yearsLDADomains positively associatedDomains not associated
Disease activity indexExclusion of New activityMajor Organ ExclusionPGAPDN daily doseIS useAM useMinimal duration
Golder et al39APLC201717072.2SLEDAI<=4YesYes<=1<=7.5AllowedAllowedNRSF-36: PCS and MCS Multivariable role physical, bodily pain, general health, social functioning, role emotional, vitality, mental health univariableSF-36: Physical function univariable
Poomsalood et al24Thailand2019237Cross-sectionalC-SLEDAI=0AllowedNR<=5AllowedAllowed1 year1 yearSLEQOL: Physical, activities, symptom, treatment, mood, self-image, total QoL univariable, LLDAS vs no LDA
b: 20.02, p=0.003 Multivariable
Ugarte-Gil et al25USA2019472NRSLAM<=3NoNoNR<=7.5Not allowedAllowedNRSF-36: PCS, MCS, physical functioning, role physical, bodily pain, general health, social functioning, role emotional, vitality, mental health
Ugarte-Gil et al33Peru20202432SLEDAI<=4NoNoNR<=7.5AllowedAllowedat least onceLupusQoL: Physical health, pain, planning, burden to others, emotional health, fatigueLupusQoL: Intimate relationship, body image
Louthrenoo et al42Thailand20203373.2SLEDAI<=4YesYes<=1<=7.5AllowedAllowedNRGlobal and all domains of SLEQOL, PCS and MCS SF-36
Kang et al43Korea20212994C-SLEDAI<=1NRNRNR5AllowedAllowedNRPCS and MCS SF-36
Kang et al43Korea20212994C-SLEDAI<=2NRNRNR0Not allowedAllowedNRPCS and MCS SF-36
Kang et al43Korea20212994SLEDAI<=4YesYes<=1<=7.5AllowedAllowedNRPCS and MCS SF-36
  • *If an article included more than one definition, a row per definition is included.

  • AM, antimalarials; HRQoL, health-related quality of life; IS, immunosuppressive drug; LDAS, low disease activity; LLDAS, lupus low disease activity state; ;MCS, Mental Component Summary; NR, not reported; PCS, Physical Component Summary; PDN, prednisone; PGA, Physician Global Assessment; SF-36, 36-Item Short Form Health Survey; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.